THE SAGE GROUP LLC Announces that Mary L. Yost, President, will Lecture on Peripheral Artery Disease (PAD) Prevalence and Economics at the NEW CARDIOVASCULAR HORIZONS Conference

ATLANTA, May 2, 2012 (BUSINESS WIRE)—THE SAGE GROUP LLC announced today that Mary L. Yost will present a lecture titled, “What is PAD’S Prevalence and Overall Economic Impact?” at the thirteenth annual New Cardiovascular Horizons (NCVH) conference held June 6-9, 2012at The New Orleans Marriott in New Orleans, Louisiana. Ms. Yost will speak June 6th at the General Session, “Assessing the Incidence, Cardiovascular and Economic Ramifications of PAD”.

About NEW CARDIOVASCULAR HORIZONS

NCVH is a peripheral intervention conference focusing on PAD (peripheral artery disease) with a special emphasis on critical limb ischemia (CLI). A unique “head-to-toe” meeting, NCVH brings together a multidisciplinary team of health professionals to focus on total cardiovascular care in patients with PAD and CLI.

PAD’S Prevalence and Economic Impact

In addition to the U.S. prevalence, Ms. Yost’s presentation will highlight PAD prevalence in selected international markets as well as analyze the current interventional market for treatment of PAD and CLI emphasizing the role of amputation.

Assessment of the economic burden includes the total annual costs of inpatient and outpatient treatments and medications, as well as hospital costs related to PAD-specific treatments, cardiovascular disease events and therapies and all-cause hospitalizations. The total economic burden of PAD is compared with that of coronary artery disease and cerebrovascular disease.

About PAD

PAD, also known as peripheral vascular disease (PVD), is characterized by a reduction of blood flow to the lower limbs due to atherosclerosis. PAD is also sometimes known as peripheral arterial obstructive disease (PAOD).

In the severe stages of PAD (critical limb ischemia or CLI) blood flow is so inadequate that ulcerations and gangrene occur. Once PAD has progressed to CLI, the risks of limb loss and mortality increase.

About THE SAGE GROUP

THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic disease in the lower limbs, specifically PAD (Peripheral Artery Disease), CLI (Critical Limb Ischemia) and ALI (Acute Limb Ischemia) as well as PAD and diabetic foot ulcers (DFU). The most recently published economic research is “The Real Cost of Peripheral Artery Disease”.
For additional information visit www.thesagegroup.us.

SOURCE: THE SAGE GROUP

THE SAGE GROUP, Atlanta
Mary Yost, 404-520-6652
yost@thesagegroup.us